Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid an­ti­body

At the two-year mark, Roche’s Evrys­di (ris­diplam) ei­ther main­tained or im­proved mo­tor func­tion from a one-year check-up in pa­tients aged 2 to 25 with Types 2 or 3 spinal mus­cu­lar at­ro­phy, the Swiss drug­mak­er said Tues­day.

Even bet­ter, Evrys­di showed no new long-term safe­ty sig­nals, and pa­tients in the sec­ond year of treat­ment ac­tu­al­ly post­ed few­er se­vere side ef­fects than in the first year, Roche said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.